The study was approved by the Ethics Committee (Krakow District Medical Chamber, Poland; 26/KBL/OIL/2011), and all participants gave written informed consent in compliance with the Declaration of ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Blood thickening, or hypercoagulability, occurs when excess cells or clotting proteins make blood more viscous, increasing ...

Meanwhile, Sanofi is also hoping to file for approval of Alnylam-partnered RNA interference therapy fitusiran for haemophilia A and B this year, which works by suppressing antithrombin (AT), a ...

Economy class syndrome is a condition also known as travel related Deep vein thrombosis, which forms as a result of blood ...

2005), and as a structure-anticoagulant relationship that also indicate 2-sulfated, 3-linked α-L-galactan, being a potent thrombin inhibitor mediated by antithrombin or heparin cofactor II, for marine ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

The syndrome of disseminated intravascular coagulation (DIC) is a serious hypercoagulation state that occurs in a variety of disease states, including cancer. Although DIC is often associated with ...

After hours: March 7 at 5:34:59 p.m. EST Loading Chart for GRFS ...